Fei Chen | Synthetic Biology | Cost-effectiveness Award

Fei Chen | Synthetic Biology | Cost-effectiveness Award

Dr. Fei Chen, Beijing Institute of Genomics, China.

Publication profile

Scopus
Googlescholar

Education

    • Ph.D. in Biology (Institution: CAS)Β πŸŽ“
    • Postdoctoral Researcher in GenomicsΒ πŸ”¬

Experience

    • Professor (PI) at Beijing Institute of Genomics, CAS 🏫
    • Chief Scientist, National Key R&D ProgramΒ πŸ§‘β€πŸ”¬
    • Editorial Board Member of multiple international journalsΒ πŸ“š
    • Principal Investigator for over 30 funded research projectsΒ πŸ’Ό

Suitability For The Award

Dr. Fei Chen is an outstanding candidate for the Cost-Effectiveness Award due to his ability to maximize scientific impact and innovation while efficiently utilizing resources. His exemplary track record of high-impact research in genomics, biosecurity, and synthetic biology demonstrates strategic allocation of funding and significant contributions to addressing critical global health challenges. Dr. Chen’s leadership in research projects, prolific publication record, and innovative patents showcase his commitment to advancing science with optimal resource management.

Professional DevelopmentΒ 

Awards and Honors

  • Chinese Medical Science and Technology AwardΒ πŸ†
  • Huaxia Medical Science and Technology AwardΒ πŸ…
  • CAS “Hundred Talents Program” (Category A) RecruitmentΒ πŸŽ–οΈ
  • National Key R&D Program Chief ScientistΒ πŸ‘¨β€πŸ”¬
  • Over 20 authorized patents, including 4 PCT patentsΒ πŸ“œ

Publications

  • Database Resources of the National Genomics Data Center, China National Center for Bioinformation in 2024 – Nucleic Acids Research, 2024, 52(1 D), cited by 50Β πŸ“šπŸ§¬
  • HervD Atlas: A curated knowledgebase of associations between human endogenous retroviruses and diseases – Nucleic Acids Research, 2024, 52(D1), cited by 5Β πŸ”¬πŸ§ͺ
  • Spatiotemporal single-cell transcriptomic profiling reveals inflammatory cell states in a mouse model of diffuse alveolar damage – Exploration, 2023, 3(3), cited by 11Β πŸπŸ”
  • Comparative transcriptome analysis of SARS-CoV-2, SARS-CoV, MERS-CoV, and HCoV-229E identifying potential IFN/ISGs targets for inhibiting virus replication – Frontiers in Medicine, 2023, 10, cited by 0Β πŸ¦ πŸ§‘β€βš•οΈ
  • Genomic epidemiology and heterogeneity of Providencia and their bla NDM-1-carrying plasmids – Emerging Microbes and Infections, 2023, 12(2), cited by 4 🧬🦠
  • Proteomic analyses of smear-positive/negative tuberculosis patients uncover differential antigen-presenting cell activation and lipid metabolism – Frontiers in Cellular and Infection Microbiology, 2023, 13, cited by 0Β πŸ©ΊπŸ’Š
  • Comparative genomic analysis reveals differential genomic characteristics and featured genes between rapid- and slow-growing non-tuberculous mycobacteria – Frontiers in Microbiology, 2023, 14, cited by 0Β πŸ§«πŸ”¬